Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00859547 · ClinicalTrials.gov registry record · Phase 4
Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants
A Phase 4 study, sponsored by ZymoGenetics.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00859547 is a Phase 4 study that has completed, run by ZymoGenetics. The registered enrollment target is 30 participants.
The verdict
NCT00859547, a Phase 4 study, has completed, sponsored by ZymoGenetics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The objective of this study is to assess the safety and immunogenicity of recombinant thrombin (rThrombin) administered as an aid to hemostasis during burn wound excision and skin grafting in pediatric patients, newborn through 17 years of age.
Interventions
- BIOLOGICAL rThrombin, 1000 IU/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00859547
The ClinicalTrials.gov registry entry for NCT00859547 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ZymoGenetics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rThrombin, 1000 IU/mL is the first listed.
NCT00859547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00859547 about?
NCT00859547 is a clinical study titled "Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants". The objective of this study is to assess the safety and immunogenicity of recombinant thrombin (rThrombin) administered as an aid to hemostasis during burn wound excision and skin grafting in pediatric patients, newborn through 17 years of age.
What is the current status of trial NCT00859547?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2009-03. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00859547?
The interventions under investigation include: rThrombin, 1000 IU/mL (BIOLOGICAL).
Who is sponsoring clinical trial NCT00859547?
This trial is sponsored by ZymoGenetics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.